

## High CVD risk in patients with head, neck squamous cell cancer

2 February 2017



uncontrolled blood pressure. Forty-one and 30 percent of patients with CVD were not taking antiplatelet therapy or statin therapy, respectively. Indications for initiating statin therapy were seen for 34 percent of patients with CVD.

"Patients with HNSCC have a high baseline CVD risk and many do not receive optimal preventive care," the authors write.

More information: Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

(HealthDay)—Twenty-three percent of patients with head and neck squamous cell carcinoma (HNSCC) have cardiovascular disease (CVD) at diagnosis, and 24 percent have uncontrolled blood pressure, according to research published online Dec. 29 in *Head & Neck*.

Christian C. Okoye, M.D., from Case Western Reserve University in Cleveland, and colleagues retrospectively reviewed patients with HNSCC who underwent definitive or adjuvant (chemo)radiation between 2011 and 2013. The authors calculated the 10-year risk estimates for a <u>cardiovascular disease</u> event according to the Framingham Risk Score (FRS).

One hundred fifteen patients with mainly stage III/IV HNSCC were followed up for a median of two years. The researchers found that 23 percent of patients had CVD at diagnosis. Patients with laryngeal cancer had higher FRS than those with cancer at other sites (20.5 versus 14.4 percent). At diagnosis, 24 percent of all patients had



APA citation: High CVD risk in patients with head, neck squamous cell cancer (2017, February 2) retrieved 5 May 2021 from <a href="https://medicalxpress.com/news/2017-02-high-cvd-patients-neck-squamous.html">https://medicalxpress.com/news/2017-02-high-cvd-patients-neck-squamous.html</a>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.